MediPharm Labs Applies for NASDAQ Listing

Extraction firm MediPharm Labs [stock_market_widget type="inline" template="generic" color="default" assets="LABS.TO" markup="(TSX: {symbol} {currency_symbol}{price} ({change_pct}))" api="yf"] has filed an application to list its common shares on the NASDAQ stock market.

The company needs to gain approval from the NASDAQ and from the United States Securities and Exchange Commission in order to secure the listing. It plans to maintain its listing on the TSX and concurrently boost its appeal to investors around the globe with a presence on the NASDAQ.

“Listing alongside our peers on the NASDAQ will enhance our visibility and access to a larger base of institutional and retail shareholders in the U.S. and globally,” said chief executive Pat McCutcheon.

Most pot stocks have listed in Canada and few have gone for a listing on the NASDAQ, with marijuana still illegal at a federal level in the U.S. It was the original electronic exchange and it has long been synonymous with technology and biotechnology, and the majority of NASDAQ-listed cannabis companies operate in the biotech sector of the industry.

They include Arena Pharmaceuticals, Cara Therapuetics, and Corbus Pharmaceuticals. Cronos Group and Village Farms International are listed, but they primarily have interests in tobacco and farming, respectively.

British company GW Pharmaceuticals is listed on the NASDAQ, but it produces the only medical cannabis product with FDA approval. Tilray and OrganiGram are the main cannabis companies currently listed.

The Green Organic Dutchman has applied to join that group, while The Flowr Corp. secured approval earlier this year, but it is now assessing the timing of the uplisting after cancelling a stock sale due to prevailing market conditions.

MediPharm Labs was founded in 2015 and it has emerged as one of the largest extraction specialists in Canada. Its share price stood at $1.80 at the start of the year and peaked at $7.39 before a correction sent it back below the $5 mark.

LABS closed at $4.53 yesterday, but opened at $4.65 today and quickly increased to $4.80 after news of the NASDAQ application was announced.

The firm generated pre-tax net income of $4.1 million in Q2 2019 after enjoying a sharp sequential increase in revenue. It is due to announced its Q3 financials later this month.

0 0 votes
Article Rating

The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Capital 10X hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.

Martin Green
Martin Green is an experienced journalist with a strong focus on the cannabis, alcohol, and gambling industries. He is particularly interested in the political issues affecting the global marijuana trade, and he has a keen focus on regulation changes and legal topics. He holds a BA English Literature, MA Creative Writing and a National Qualification in Journalism diploma. He has worked in journalism since 2009 and written for a broad range of newspapers, business titles and magazines, including The Sun, The Metro, The Journal, Livestrong, Drinks Retailing News, Harpers, Sportsbook Review, Vital Football, Essex Live and Surrey Live. Address: 682 Indian Road, Toronto, Ontario, M6P 2C9. Phone: 416-721-8257.
Notify of
Inline Feedbacks
View all comments